Claims
- 1. A method for reducing bone loss in a mammalian subject, the method comprising administering an effective amount of an inhibitor of 15-lipoxygenase to the subject.
- 2. The method of claim 1, wherein bone loss is associated with osteoporosis, osteoarthritis, Paget's disease, or periodontal diseases.
- 3. The method of claim 2, wherein bone loss is associated with osteoporosis.
- 4. A method of increasing bone mineral density in a mammal by administering to the mammal an effective amount of an inhibitor of 15-LO.
- 5. A method of reducing the incidence of fracture in a mammal by administering to the mammal an effective amount of an inhibitor of 15-LO.
- 6. A method of healing fractures in a mammal by administering to the mammal an effective amount of an inhibitor of 15-LO
- 7. A method of treating osteoporosis in a mammal by administering to the mammal an effective amount of an inhibitor of 15-LO.
- 8. The method of any of claims 1-7, wherein the mammal is a human.
- 9. The method of claim 8, wherein the inhibitor of 15-LO has an IC50 of less than 1 μM.
- 10. The method of claim 1, further comprising administering an additional active agent.
- 11. The method of claim 10, wherein the additional active agent is effective to regulate calcium resorption from bone.
- 12. The method of claim 11, wherein the additional active agent is selected from a group consisting of an estrogen, a calcitonin, a bisphosphonate, and an IGF.
- 13. A method for identifying compounds that increase bone mineral density, the method comprising contacting a compound with 15-LO and determining whether the compound inhibits 15-LO.
- 14. The method of claim 13, further comprising testing the compound in a functional assay that demonstrates an effect of the compound on bone formation.
- 15. The method of claim 14, wherein the functional assay comprises contacting the compound with human mesenchymal stem cells and determining cellular differentiation into bone forming cells.
- 16. The method of claim 14, wherein the functional assay comprises administering the compound to a non-human animal and measuring an index of bone formation.
- 17. The method of claim 16, wherein the index measured is bone mineral density.
- 18. The method of claim 16, wherein the index is a biomechanical parameter of bone.
- 19. The method of claim 15, wherein determining cellular differentiation comprises performing an alkaline phosphatase assay, a calcium assay, a total DNA preparation assay, or combinations thereof.
- 20. A method for identifying compounds that increase bone mineral density, the method comprising contacting an inhibitor of 15-lipoxygenase with human mesenchymal stem cells and determining cellular differentiation into bone forming cells.
- 21. The method of claim 20, wherein determining cellular differentiation comprises performing an alkaline phosphatase assay, a calcium assay, a total DNA preparation assay, or combinations thereof.
- 22. A method of diagnosis of predisposition to bone loss in a subject, the method comprising detecting a polymorphism on human chromosome 17, wherein the polymorphism is indicative of predisposition to bone loss.
- 23. The method of claim 22, wherein the detecting comprises genotyping.
- 24. The method of claim 23, wherein the genotyping consists of microsatellite markers or one or more single nucleotide polymorphisms.
- 25. A method of monitoring the efficacy of treatment to reduce bone loss or heal fractures in a subject comprising measuring the level of 15-LO in the subject.
- 26. A method of diagnosis of predisposition to bone loss in a subject, the method comprising detecting a polymorphism in the 15-LO gene of the subject.
- 27. A method of promoting differentiation of mesenchymal stem cells in a human to osteoblasts comprising administering to the human an effective amount of an inhibitor of 15-LO to increase the osteoblasts in said human.
- 28. The method of claim 27, wherein the inhibitor of 15-LO has an IC50 of less than 1 μM.
CROSS-REFERENCE TO RELATED INVENTION(S)
[0001] This application claims the priority benefit under Title 35 U.S.C. 119(e) of U.S. Provisional Application Serial No. 60/355,255, filed Feb. 8, 2002, the disclosure of which is herein incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60355255 |
Feb 2002 |
US |